CClinicalTrials.gg
CompletedNCT03590132SAAF-STEPSUpdated Jun 19, 2019

Strong African American Families STEPS Project

A Phase 4 interventional study of Strong African American Families Program and Strong African American Families--Teen Program in Adolescent Alcohol Use, sponsored by University of Georgia. Completed. Open to participants aged 11 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-19.

Sponsored by University of Georgia · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
11 Years to 13 Years
Sex
All
01

Study summary

The most common approach to preventing alcohol use involves providing a well-designed program in preadolescence just prior to or upon entering middle school. This approach does not have long-lasting effects or address the risk factors that lead many youth to use alcohol in high school. This study tested a strategy that compares offering effective programs at the transition to middle school and the transition to high school with only offering a program at either one of the transitions or no programs at all.

Read the detailed description

Alcohol use is a leading cause of morbidity and mortality among high school students. Annually, underage drinking leads to more than 3,000 deaths and 2.6 million other harmful events, resulting in $5.4 billion in medical costs, $14.9 billion in work loss and other resource costs, and $41.6 billion in lost quality of life. This public health crisis has engendered considerable attention from prevention scientists, who have specified guidelines for the development of primary prevention programs and the timing of their implementation. The present research is based on critical limitations in the prevailing model for implementing primary prevention for alcohol use. This model focuses on delaying alcohol use onset among youth who begin use in middle school (ages 11-14). Based on studies that linked early use to a high-risk behavioral trajectory in adolescence, prevention scientists translated data on risk and protective processes for early-onset alcohol use into primary prevention programs for youth to be implemented during or just prior to the transition to adolescence. This model has informed numerous randomized prevention trials and investigations of prevention implementation. An unquestioned premise of this model involves the adequacy of a single preadolescent "inoculation" of prevention programming to protect youth into the high school years.

The proposed trial addresses empirical and theoretical limitations to the preadolescent/single inoculation paradigm. First, inclusive reviews reveal that primary prevention programs implemented in early adolescence fail to achieve robust, long-term results. Second, studies of alcohol use trajectories reveal patterns of onset in high school with rapid escalation that culminate in high levels of alcohol use. Third, in the prevailing paradigm, targeting early adolescent risk processes is assumed to be sufficient to equip youth for the novel risk processes they will encounter in high school. In contrast, this study investigates the proposition that achievement of public health impact requires a "dual-inoculation" prevention strategy, one that addresses both onset in early adolescence and mid-adolescence and provides developmentally tailored curricula at each transition.

Based on longitudinal studies with rural African American families that documented the changing context of alcohol use risk and protective processes from late childhood through adolescence, scientists at the Center for Family Research developed a series of developmentally appropriate, family-centered preventive interventions that have proven efficacious in in preventing alcohol use: the Strong African American Families (SAAF) program for youth age 10-12 and the SAAF-Teen program for youth age 14-16. These programs afford a unique opportunity to test dual-inoculation hypotheses. Unlike medical inoculations of a vaccine, it is not appropriate to give the same inoculation to an 11-year-old that one gives a 14-year-old. Rather, each preventive inoculation must be tailored to address the most salient risk and protective processes at particular developmental transitions.

This study will recruit a sample of 460 African American families into a four-arm randomized prevention trial and evaluate the differential alcohol prevention effects of (a) a dual inoculation of prevention (youth receive SAAF at age 11 and SAAF-Teen at age 14) compared with (b) receipt of a preadolescent inoculation (SAAF at age 11), (c) receipt of a mid-adolescent inoculation (SAAF-Teen at age 14), or (d) a minimal contact control.

Specific efficacy aims are to:

  1. Test the hypothesis that rural African American youth randomly assigned to participate in two prevention inoculations will demonstrate lower rates of alcohol use initiation, frequency of use, binge drinking, and alcohol-related problems in high school than will youth who receive a preadolescent inoculation only, a mid-adolescent inoculation only, or no inoculations.
  2. Investigate the intervening processes that account for the relative efficacy of a dual inoculation. Specifically, we expect that intervention-targeted early adolescent protective processes, early adolescent alcohol use outcomes, and intervention-targeted mid-adolescent protective processes will account for group differences in alcohol use in high school.

    To facilitate the potential dissemination of a dual inoculation approach, this study investigates the cost-effectiveness of a dual inoculation relative to preadolescent, mid-adolescent, or control conditions.

    The specific cost-effectiveness aim is to:

  3. Conduct a cost-effectiveness analyses that estimates the incremental cost of a dual inoculation compared to single inoculations and no inoculations per additional unit decrease in alcohol use initiation, escalation, binge drinking, and alcohol-related problems. This study will investigate an ancillary hypothesis involving the incremental cost difference per outcome unit between preadolescent and mid-adolescent inoculations relative to the control condition.
02

Conditions studied

  • Adolescent Alcohol Use

Browse trials for

Keywords

  • adolescent
  • alcohol
  • family-centered prevention
  • African American
03

Who can participate

Ages eligible
11 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • self reported African American
  • 5th grade

Exclusion criteria

Exclusion Criteria:

  • unable to attend a family-centered prevention intervention due to incapacitation of youth
  • unable to attend a family-centered prevention intervention due to incapacitation of youth
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
472 participants (actual)

Study arms

  • Experimental
    SAAF

    participants in this arm receive the SAAF intervention at age 11-12.

    Behavioral: Strong African American Families Program

  • Experimental
    SAAF-T

    participants in this arm receive the SAAF-Teen intervention at age 14-15.

    Behavioral: Strong African American Families--Teen Program

  • Experimental
    SAAF SAAF-T

    participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15

    Behavioral: Strong African American Families Program · Behavioral: Strong African American Families--Teen Program

  • No intervention
    Control

    These participants receive no interventions.

Interventions

  • BehavioralStrong African American Families Program

    SAAF is a 7 session family skills training program

    Also known as: SAAF

  • BehavioralStrong African American Families--Teen Program

    SAAF-T is a 5 session family skills training program

    Also known as: SAAF--T

05

What researchers measure

Primary outcomes

  1. Alcohol use in past 3 months (single item)

    Youth complete this single item from Monitoring the Future Study assessing the frequency of alcohol use in the past 3 months. There is an ordinal response scale ranging from 0 (none) to 6 (30 or more times). Higher response numbers indicate a worse outcome (more alcohol use).

    Time frame: 3 months

  2. Frequency of cannabis use in the past 3 months (single item)

    Single item from Monitoring the Future Study assessing frequency of marijuana use in the past 3 months. There is an ordinal response scale ranging from 0 (none) to 6 (30 or more times). Higher responses indicate a worse outcome (more marijuana use in the past 3 months).

    Time frame: 3 months

  3. Monitoring the Future: Total substance use (summative index of use of alcohol, cannabis, and nicotine)

    Youth complete 3 single items from the Monitoring the Future study indexing the frequency of their use of alcohol, cannabis, and nicotine in past 3 months. There is an ordinal response scale ranging from 0 (none) to 6 (30 or more times) for each item. The three items are summed yielding a scale ranging from 0-18. Higher response numbers indicate a worse outcome (more substance use).

    Time frame: 3 months

Secondary outcomes

  1. Center for Epidemiological studies-Depression scale

    Parent complete this 20 item measure of depressive symptoms. Responses to each item are on a scale from 0 to 3; responses are summed. Items are summed. Scores range from 0-60 with higher scores indicate more depressive symptoms in the past week (a worse outcome).

    Time frame: Past 7 days

  2. The National Survey of Adolescents Conduct Problems Subscale

    Youth complete a 15 Item scale from the National Survey of Adolescents which refer to different conduct problems. Youth provide the number of times they enacted each behavior in the past 3 months. These responses are summed. Scores can range from 0-99 with higher scores indicating more engagement in conduct problems.

    Time frame: past 3 months

  3. Center for Epidemiological Studies-Depression Scale-Child Version

    Youth complete this 20 item measure of depressive symptoms. Responses to each item are on a likert scale from 0 to 3; responses are summed. Scores range from 0-60 with higher scores indicate more depressive symptoms in the past week (a worse outcome).

    Time frame: past 7 days

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No — Participants have not consented to data being shared outside of research team

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03590132
Lead sponsor
University of Georgia
Responsible party
Steve Kogan (Professor, University of Georgia) — Principal investigator
First posted
Jul 18, 2018
Start date
Dec 10, 2012
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018
Last update
Jun 19, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion